Price (delayed)
$11.04
Market cap
$2.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$3.03B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of
There are no recent dividends present for BCRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.